CHMP Gives Nod to New Drugs in Cancer CareCHMP Gives Nod to New Drugs in Cancer Care
Marketing authorization has been granted in Europe for generic versions of busulfan and filgrastim and for expanded use of denosumab. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 28, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
U.S. paves way for Novartis to copy Amgen biotech drug
(Reuters) - U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for patients with low white blood cell counts. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Pegfilgrastim-Induced Pain in Patients With LymphomaPegfilgrastim-Induced Pain in Patients With Lymphoma
Growth factors, such as pegfilgrastim or filgrastim, have reduced the incidence, duration, and severity of chemotherapy-related neutropenia, but what are the common side effects? Oncology Nursing Forum (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2014 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news
How Can You Treat Low Neutrophil Count?
Neupogen (filgrastim) is a drug given to patients who have neutropenia (low neutrophil count). An injection of Neupogen stimulates white blood cell production. It is a clear liquid that is usually given as an injection. Learn how Neupogen helps boost your neutrophil count. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - May 2, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
What’s the Difference Between Neulasta...
Chemotherapy can cause your neutrophil counts to drop, which puts you at risk of infection. Neutropenia is treated with Neulasta or Neupogen, but what's the difference, and how do you choose? Read more to understand your choices. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - May 1, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
How Will My Doctor Decide Whether I Need...
Chemotherapy can cause your neutrophil counts to drop, which puts you at risk of infection. Neutropenia is treated with Neulasta or Neupogen, but what's the difference, and how do you choose? Read more to understand your choices. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - December 30, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Oncology Leads Biosimilars Market Growth to 2018 Forecasts in New...
RnRMarketResearch.com adds “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides...(PRWeb December 05, 2013)Read the full story at http://www.prweb.com/releases/2018-biosimilars-market/market-report/prweb11395443.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 6, 2013 Category: Pharmaceuticals Source Type: news
Neupogen (Filgrastim) – Treatment for Low...
Neupogen (filgrastim) is a drug given to patients who have neutropenia (low neutrophil count). An injection of Neupogen stimulates white blood cell production. It is a clear liquid that is usually given as an injection. Learn how Neupogen helps boost your neutrophil count. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - November 4, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Stada widens biotech drug offering with filgrastim license
FRANKFURT (Reuters) - Germany's Stada will sell a version of U.S. drugmaker Amgen's blockbuster cancer treatment filgrastim in Europe, keeping faith with the difficult market for copies of medicines developed using biotechnology. (Source: Reuters: Health)
Source: Reuters: Health - October 28, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Amgen acquires sales rights to Roche's Neupogen and Neulasta in 100 markets
US-based biotechnology firm Amgen (AMGN) has acquired sales rights to Swiss drugmaker Roche's two drugs Neupogen (filgrastim) and Neulasta (pegfilgrastim), which are used to boost the immune systems of cancer patients on chemotherapy in more than 100… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 23, 2013 Category: Pharmaceuticals Source Type: news
EU Okays Afatinib for NSCLC, Filgrastim and DefibrotideEU Okays Afatinib for NSCLC, Filgrastim and Defibrotide
The European Committee for Medicinal Products for Human Use has issued new positive opinions for 3 products used to treat cancer patients. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Updated national IV monograph on Filgrastim (Zarzio)
Source: Medusa
Area: News
An updated IV monograph on Filgrastim (Zarzio) is now available from the NHS injectable medicines guide website (Medusa). Please see the link below for access (registration required). (Source: NeLM - News)
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
